Friday, 20 February 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 20 February 2026
News

Seqirus wipes out rival's patents

Posted 20 February 2026 AM

CSL Seqirus has succeeded in ending two of Moderna's Australian patents covering mRNA vaccines.

Last July the home-grown giant successfully challenged the two patents, Nucleic acid vaccines (AU553) and high purity RNA compositions and methods for preparation of these compositions (AU423) at the Australian Patent Office, although Moderna was given a chance to amend the patents to be valid.

To see the whole article, please login

Popular

Is this pharma's hottest career?
Roche taps Aussie for big HQ job
Look who's won a leadership role
Meet Pharma's Most Influential
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (14)

Clinical & Medical, R&D (4)

Regulatory, Pharmacovigilance & QA (3)

Other (17)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home